Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

58.95 +0.56 (+0.96%)
Streaming Delayed Price Updated: 12:22 PM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Recap: Biomarin Pharmaceutical Q3 Earnings
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Expert Ratings for Biomarin Pharmaceutical
Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter: 
Via Benzinga
One Rejected BioMarin's Hemophilia Gene Therapy Goes Under FDA Review
Via Benzinga
BioMarin Lays Off 4% Of Its Workforce To 'Simplify' The Company
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Expert Ratings for Biomarin Pharmaceutical
Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings: 
Via Benzinga
BioMarin Lifts Annual Guidance On Better Than Expected Q2 Earnings
Via Benzinga
Analyst Ratings for Biomarin Pharmaceutical
Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings: 
Via Benzinga
BioMarin Says One Participant Diagnosed With Leukemia In Late-Stage Hemophilia Gene Therapy Trial
Via Benzinga
Neurocrine Leads 5 Stocks To Watch In Sickly Market
Neurocrine Biosciences leads five medical stocks showing resilience. 
Via Investor's Business Daily
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
BioMarin Receives European Commission's Conditional Marketing Authorization For Gene Therapy Candidate
The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ: BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the... 
Via Benzinga
Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart
  If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Undervalued Biotech Stocks to Buy Before They Boom
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy. 
Via InvestorPlace
Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them
Four pharmaceutical stocks, including three biotech movers, are making big moves. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
What 4 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter: 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:... 
Via Benzinga
BioMarin Achieves Record Q1 Sales Driven By Recently Approved Achondroplasia Therapy
Via Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Biomarin Pharmaceutical Earnings Preview
Biomarin Pharmaceutical (NASDAQ:BMRN) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Keybanc cut Salesforce, Inc. (NYSE: CRM) price target from $281 to $223. Salesforce shares fell 1.1% to $169.60 in pre-market trading. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
A Bearish Sign Appears On Biomarin Pharmaceutical's Chart
If history is any guide, there may be trouble ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish... 
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.